Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SERPANRAY vs ALDORIL D30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Serotonin-dopamine activity modulator; partial agonist at 5-HT1A and D2 receptors, antagonist at 5-HT2A receptors.
Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.
FDA: Adjunctive treatment of schizophrenia in adults.,Off-label: Bipolar I disorder (maintenance), major depressive disorder (adjunctive), Tourette syndrome, obsessive-compulsive disorder, post-traumatic stress disorder, autism-associated irritability.
Hypertension
1.5 mg orally once daily at bedtime, titrated up to a maximum of 3 mg once daily.
Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.
Terminal elimination half-life is approximately 62 hours following oral administration, allowing for once-daily dosing.
Terminal elimination half-life of hydrochlorothiazide is 6-15 hours; methyldopa half-life is 1.8 hours (normal renal function). In renal impairment, half-life of both components is prolonged.
Primarily metabolized by CYP3A4 and CYP2D6; minor pathways include CYP1A2 and CYP2C19.
Methyldopa is metabolized by conjugation (catechol-O-methyltransferase) and hepatic sulfation; hydrochlorothiazide is not extensively metabolized and is excreted unchanged by the kidney.
Primarily hepatic metabolism via CYP1A2 and CYP3A4, with 18% excreted unchanged in urine and 26% in feces as metabolites.
Renal: approximately 50% as parent drug and metabolites; biliary/fecal: minimal, less than 5%.
99.5% bound to albumin and alpha-1-acid glycoprotein.
Methyldopa: <10% bound to plasma proteins; hydrochlorothiazide: 40-68% bound to albumin.
Apparent Vd is 4.0 L/kg, indicating extensive tissue distribution beyond plasma volume.
Methyldopa: Vd 0.2-0.3 L/kg (distributes into tissues, crosses placenta); hydrochlorothiazide: Vd 0.75-1.5 L/kg (extensively distributed, does not cross blood-brain barrier significantly).
Oral bioavailability is 30–40% due to first-pass metabolism.
Oral bioavailability of methyldopa is approximately 25% (variable, influenced by gut metabolism); hydrochlorothiazide bioavailability is 65-75%.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). For severe renal impairment (Cr Cl <30 m L/min), use is not recommended due to lack of data.
GFR 30-60 m L/min: reduce dose by 50%; GFR <30 m L/min: not recommended.
Child-Pugh Class A: No dosage adjustment. Child-Pugh Class B: Reduce dose to 1 mg once daily, may increase to 1.5 mg based on tolerability. Child-Pugh Class C: Use is not recommended.
Child-Pugh Class B or C: contraindicated; use not recommended.
Not approved for pediatric patients below 18 years of age; no specific dosing guidelines available.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Elderly patients may be more sensitive to sedative and orthostatic hypotensive effects. Initiate at 1 mg once daily, titrate cautiously. Maximum dose 1.5 mg once daily for patients >65 years.
Start with lowest dose; monitor for hypotension, electrolyte imbalance, and CNS effects; consider reduced initial dose.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. SERPANRAY is not approved for the treatment of dementia-related psychosis.
None
Cerebrovascular adverse events in elderly dementia patients; neuroleptic malignant syndrome; tardive dyskinesia; metabolic changes (hyperglycemia, dyslipidemia, weight gain); hyperprolactinemia; orthostatic hypotension; leukopenia/neutropenia/agranulocytosis; seizures; body temperature dysregulation; dysphagia; falls; cognitive and motor impairment; increased mortality in elderly with dementia.
May cause hemolytic anemia, liver disorders, positive Coombs test, sedation, depression, and hypersensitivity reactions. Hydrochlorothiazide may cause electrolyte imbalance, hyperuricemia, photosensitivity, and exacerbation of systemic lupus erythematosus. Use with caution in renal impairment, hepatic disease, and in patients with a history of drug-induced hemolytic anemia.
Hypersensitivity to SERPANRAY or any of its components; concomitant use with strong CYP3A4 inducers or inhibitors (due to potential for significant drug interactions); history of severe allergic reactions (e.g., anaphylaxis, angioedema) to SERPANRAY.
Active hepatic disease, history of previous methyldopa therapy-associated liver disorders; anuria; hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamide-derived drugs.
Take with food to enhance absorption. High-fat meals increase lumateperone exposure. Avoid grapefruit juice as it may increase drug levels.
Food may decrease absorption of methyldopa. Avoid excessive intake of high-potassium foods (e.g., bananas, oranges) unless directed. Hydrochlorothiazide may cause potassium depletion; maintain adequate dietary potassium. Avoid natural licorice as it can worsen hypokalemia.
First trimester: No adequate human data; animal studies not available. Risk cannot be excluded. Second/third trimester: No data; consider risks versus benefits. Pregnancy category N (not classified by FDA due to lack of data).
First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; possible fetal bradycardia and neonatal hypotension. Hydrochlorothiazide may cause fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances.
No data on presence in human milk, effects on breastfed infant, or milk production. M/P ratio unknown. Caution recommended; consider alternative agents.
Methyldopa is excreted in breast milk in low concentrations; M/P ratio approximately 0.2. Hydrochlorothiazide is excreted in minimal amounts; may suppress lactation. Consider risks versus benefits.
No pharmacokinetic studies in pregnancy; dose adjustments not established. Use lowest effective dose if required. Monitor for clinical response and adverse effects.
Methyldopa: Pregnancy-induced plasma volume expansion may require dose titration; monitor blood pressure and adjust accordingly. Hydrochlorothiazide: Often avoided in pregnancy due to volume depletion risks; if used, monitor electrolytes and renal function, no pharmacokinetic data necessitate routine dose adjustment.
SERPANRAY (lumateperone) is an atypical antipsychotic with a unique receptor binding profile (5-HT2A antagonist, D2 antagonist, and SERT inhibitor). It is indicated for schizophrenia and bipolar depression. Dosing is fixed at 42 mg once daily with food. No dose titration required. Common side effects include somnolence, sedation, and dry mouth. Monitor for metabolic changes, extrapyramidal symptoms, and tardive dyskinesia. Avoid use in hepatic impairment (Child-Pugh B or C).
ALDORIL D30 combines methyldopa (central alpha-2 agonist) and hydrochlorothiazide (thiazide diuretic). Monitor for orthostatic hypotension, especially at initiation. Taper not needed for methyldopa but discontinue if fever or liver dysfunction occurs. Interferes with urinary catecholamine measurements (false elevation). Hydrochlorothiazide may cause hyponatremia, hypokalemia, and hyperglycemia; check electrolytes and glucose periodically.
Take SERPANRAY exactly as prescribed once daily with food.,Do not stop taking this medicine without talking to your doctor.,This medicine may cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Rise slowly from a sitting or lying position to minimize dizziness.,Inform your doctor immediately if you experience muscle stiffness, fever, confusion, or uneven heartbeat.,Avoid alcohol while taking SERPANRAY.
Take exactly as prescribed, preferably with food to reduce stomach upset.,Rise slowly from sitting or lying down to prevent dizziness.,This drug may make you drowsy; avoid driving or operating machinery until you know how it affects you.,Report fever, unexplained fatigue, jaundice, or dark urine immediately.,Weigh yourself daily and report rapid weight gain or swelling.,Limit alcohol intake as it can increase side effects.,Do not use salt substitutes containing potassium without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SERPANRAY vs ALDORIL D30, answered by our medical review team.
SERPANRAY is a Antihypertensive that works by Serotonin-dopamine activity modulator; partial agonist at 5-HT1A and D2 receptors, antagonist at 5-HT2A receptors.. ALDORIL D30 is a Antihypertensive Combination that works by Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SERPANRAY and ALDORIL D30 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SERPANRAY is: 1.5 mg orally once daily at bedtime, titrated up to a maximum of 3 mg once daily.. The standard adult dose of ALDORIL D30 is: Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SERPANRAY and ALDORIL D30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SERPANRAY is classified as Category C. First trimester: No adequate human data; animal studies not available. Risk cannot be excluded. Second/third trimester: No data; consider risks versus benefits. Pregnancy category . ALDORIL D30 is classified as Category C. First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.